Neurofilaments are proteins selectively expressed in the cytoskeleton of neurons, and increased levels are a marker of damage. Elevated neurofilament levels can serve as a marker of ongoing disease activity as well as a tool to measure response to therapeutic intervention. The potential utility of neurofilaments has drastically increased as recent advances have made it possible to measure levels in both the cerebrospinal fluid and blood. There is mounting evidence that neurofilament light chain (NfL) and phosphorylated neurofilament heavy chain (NfH) are abnormal in a host of neurodegenerative diseases. In this review we examine how both of these proteins behave across diseases and what we know about how these biomarkers relate to in vivo white matter pathology and each other.

Original languageEnglish
Pages (from-to)105-115
Number of pages11
JournalCurrent Opinion in Neurobiology
StatePublished - Apr 2020


Dive into the research topics of 'Neurofilaments in disease: what do we know?'. Together they form a unique fingerprint.

Cite this